Farhad Peerani
Contact
Assistant Professor, Faculty of Medicine & Dentistry - Medicine Dept
- peerani@ualberta.ca
Overview
Area of Study / Keywords
IBD disease pathophysiology drug monitoring therapeutic efficacy safety elderly primary sclerosing cholangitis
About
Dr. Farhad Peerani graduated from the University of British Columbia’s medical program and completed residencies in internal medicine and gastroenterology at the University of Alberta. He pursued an advanced two-year clinical research Inflammatory Bowel Disease (IBD) Fellowship at both the University of Alberta and Mount Sinai Hospital in New York City. This training was supported by the Canadian Institutes of Health Research and the Canadian Association of Gastroenterology Fellowship Award. He was subsequently appointed Assistant Professor of Medicine at the University of Alberta on July 1, 2016.
Dr. Peerani allocates 30 percent of his time to research focusing on various aspects of inflammatory bowel disease. He has published several peer-reviewed scientific articles and has presented on a range of research topics from endoscopic scoring systems in inflammatory bowel disease to real-world efficacy of biologic therapies.
Leadership and Collaborations:
Dr. Peerani is the Gastrointestinal and Liver Disease Research Group IBD Clinical Trials Lead and serves as principal investigator and sub-investigator on numerous multi-center clinical trials. He is also a member of the Canadian IBD Research Consortium.
Clinical Interests
Dr. Peerani is a gastroenterologist with
Research
Dr. Peerani’s research interests include studying the pathophysiology of elderly-onset IBD as well as investigating the safety, efficacy and management of various therapeutic regimens used in ageing IBD patients. Furthermore, he is also interested in better understanding the IBD phenotype in patients with primary sclerosing cholangitis. He has authored and co-authored several manuscripts published in journals such as Inflammatory Bowel Diseases, Gastroenterology and American Journal of Gastroenterology. He was a 2017 recipient of the University Hospital Foundation Medical Research Competition for a clinical study assessing the effectiveness of a stress reduction intervention in ulcerative colitis.
Featured Publications
Canadian Liver Journal. 2022 February; doi.org/10.3138/canlivj-2021-0023
Gastro Hep Advances. 2021 December; doi.org/10.1016/j.gastha.2021.11.009
Prebiotic Beta-Fructans Prevent Subclinical Intestinal Inflammation in Ulcerative Colitis Patients Who Are in Clinical Remission
Gastroenterology. 2021 May;
Shorter Disease Duration in Patients with Crohn’s Disease is Associated with Higher Rates of Remission with Ustekinumab
Gastroenterology. 2021 May;
The Real-World Effectiveness of Ustekinumab in the Treatment of Crohn’s Disease
Gastroenterology. 2021 May;
Exploring patient perspective on an online, stress reduction based wellness intervention in patients with Inflammatory Bowel Disease (IBD)
Journal of the Canadian Association of Gastroenterology. 2021 March;
Majority of Inflammatory Bowel Disease Patients with Recurrent Clostridioides Infection Do Not Require Fecal Microbiota Transplantation
Journal of the Canadian Association of Gastroenterology. 2021 March;
Balram B., Joshi H., Wong K., Kroeker K.I., Dieleman L.A., Halloran B.P., Baumgart D.C., Peerani F.
DIGESTIVE DISEASES AND SCIENCES. 2020 November; 10.1007/s10620-020-06704-6